{"id":"974c6c15-2e8e-5c1e-9d7f-ed22bd0bda28","stable_key":"cb568d28-484a-5c2e-9fcc-2d780358e514:c-oral-iv-modeled-peaks","predicate":"route_changes_predicted_high_dose_peak","statement":"The model predicted peaks of 220 micromol/L for oral 3 g every four hours and 13400 micromol/L for 50 g IV.","claim_class":"hypothesis_link","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"8abaeec6-01fc-54d1-a5ad-0cb72a526f96","mechanism_event_label":"The model illustrates why oral and intravenous experiments cannot be treated as equivalent exposures.","subject":{"id":"2047867f-9872-53b2-a553-71c911d0695b","slug":"ascorbic-acid","display_name":"L-Ascorbic acid","entity_type_key":"small_molecule"},"object":{"id":"82e3e6b4-3f0f-5fee-b37f-d076185d7b72","slug":"plasma-ascorbate-concentration","display_name":"Plasma ascorbate concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"8abaeec6-01fc-54d1-a5ad-0cb72a526f96","stable_key":"cb568d28-484a-5c2e-9fcc-2d780358e514:c-oral-iv-modeled-peaks-event","event_type":"biochemical_relationship","label":"The model illustrates why oral and intravenous experiments cannot be treated as equivalent exposures.","description":"The model predicted peaks of 220 micromol/L for oral 3 g every four hours and 13400 micromol/L for 50 g IV.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"2047867f-9872-53b2-a553-71c911d0695b","slug":"ascorbic-acid","display_name":"L-Ascorbic acid","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"82e3e6b4-3f0f-5fee-b37f-d076185d7b72","slug":"plasma-ascorbate-concentration","display_name":"Plasma ascorbate concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"experimental_model","value_text":"Seventeen healthy hospitalized volunteers; measured dose/concentration experiments plus pharmacokinetic modeling.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Measured oral/IV doses 0.015–1.25 g; modeled doses 1–100 g. Larger modeled exposures were not validated in cancer patients.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"These high-dose values were calculated, not measured in this study; no patient recommendation or proof of benefit.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Vitamin C research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"vitamin-c","display_name":"Vitamin C","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The model illustrates why oral and intravenous experiments cannot be treated as equivalent exposures.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[c-padayatty2004] Vitamin C pharmacokinetics: implications for oral and intravenous use (2004). https://pubmed.ncbi.nlm.nih.gov/15068981/ DOI: 10.7326/0003-4819-140-7-200404060-00010","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Human blood or whole-person endpoints","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"094f47cf-18f7-5c4b-ae13-631d371224fa","evidence_kind":"source_excerpt","locator":"Lines 1481-1491","start_line":1481,"end_line":1491,"excerpt":"### c-oral-iv-modeled-peaks\nThe model predicted peaks of 220 micromol/L for oral 3 g every four hours and 13400 micromol/L for 50 g IV.\nCondition category: normal\nnutrient_topic: Vitamin C research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The model illustrates why oral and intravenous experiments cannot be treated as equivalent exposures.\norganism: Homo sapiens\ntissue_or_cell_type: Human blood or whole-person endpoints\nexperimental_model: Seventeen healthy hospitalized volunteers; measured dose/concentration experiments plus pharmacokinetic modeling.\nlimitations: These high-dose values were calculated, not measured in this study; no patient recommendation or proof of benefit.\nexposure: Measured oral/IV doses 0.015–1.25 g; modeled doses 1–100 g. Larger modeled exposures were not validated in cancer patients.\n[c-padayatty2004] Vitamin C pharmacokinetics: implications for oral and intravenous use (2004). https://pubmed.ncbi.nlm.nih.gov/15068981/ DOI: 10.7326/0003-4819-140-7-200404060-00010","model_system":"Seventeen healthy hospitalized volunteers; measured dose/concentration experiments plus pharmacokinetic modeling.","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [c-padayatty2004] Vitamin C pharmacokinetics: implications for oral and intravenous use (2004). https://pubmed.ncbi.nlm.nih.gov/15068981/ DOI: 10.7326/0003-4819-140-7-200404060-00010","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"fa811221-13bd-5c10-adc1-eaf097c7703c","stable_key":"import-cb568d28-484a-5c2e-9fcc-2d780358e514","title":"Vitamin C: mechanisms, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"b7fd83f956abb81855f2ea23199ba14e465cd91f4a2ac560277ec21ddafd7bfc","revision_id":"6cde9bbb-d712-5746-82a6-85b144253efa","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}